Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Holding PCRX?
Track your performance easily
PCRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.16 - $35.95
Previous Close$17.38
Volume495.17K
Average Volume (3M)799.63K
Market Cap
$802.49M
Enterprise Value$993.10M
Total Cash (Recent Filing)$453.81M
Total Debt (Recent Filing)$644.42M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Feb 27, 2025EPS Estimate
$0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.05
Shares Outstanding46,173,240
10 Day Avg. Volume650,572
30 Day Avg. Volume799,633
Standard Deviation0.11
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.05
Price to Sales (P/S)1.11
Price to Cash Flow (P/CF)3.60
P/FCF Ratio3.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.43
Enterprise Value/Gross Profit2.03
Enterprise Value/Ebitda-66.46
Forecast
1Y Price Target
$20.67Price Target Upside17.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Pacira Pharmaceuticals News
PremiumCompany Announcements
Pacira BioSciences Reports Q3 2024 Earnings and Strategic Developments
PremiumCompany Announcements
Pacira Pharmaceuticals Faces Q3 Loss Amid Revenue GrowthBulls Say, Bears Say
Bulls Say
Financial PerformancePacira reported its second highest quarterly cash flow ever, demonstrating strong financial health and resilience.
Legal And Patent ProtectionA potential reversal of the patent ruling on appeal could block generic competition until 2041, providing a significant advantage for Pacira.
Market OpportunitiesPacira's new partnership with Vizient covers 30% of the Exparel market opportunity, highlighting a strategic move to expand its market presence.
Bears Say
Competitive RisksPacira's risk profile has significantly worsened given the lucrative opportunity for additional competitors, creating uncertainty for investors.
Patent InvalidationThe U.S. District Court for the District of New Jersey ruled that patent #11,033,495 ('495) on Exparel is invalid, allowing eVenus to launch a generic.
Sales And Revenue ImpactGeneric Exparel launch is imminent within next 12-mos, which leads analysts to cut 2025 sales estimates by 37% on Pacira's lead asset.
---
Ownership Overview
1.55% Insiders
30.33% Mutual Funds
16.45% Other Institutional Investors
11.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $11.16 and its highest was $35.95 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Currently, no data Available
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Feb 27, 2025 which is in 96 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.704 by $0.086.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is $0.78.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 46,173,240 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.79 in its last earnings report, beating expectations of $0.704. Following the earnings report the stock price went up 0.17%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Among the largest hedge funds holding Pacira Pharmaceuticals’s share is Gotham Asset Management LLC. It holds Pacira Pharmaceuticals’s shares valued at 1M.
---
Pacira Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.67 (17.78% Upside)
$20.67 (17.78% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 416.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 31.3%
Last 30 Days ▲ 31.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.80%
12-Months-Change
Fundamentals
Return on Equity
-11.48%
Trailing 12-Months
Asset Growth
-0.83%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
---
PCRX Earnings Call
Q3 2024
0:00 / 0:00
---
PCRX Stock 12 Month Forecast
Average Price Target
$20.67
▲(17.78% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Axsome Therapeutics
―
Dr Reddy's Laboratories
―
Supernus Pharmaceuticals
―
Best Analysts Covering PCRX
1 Year
1 Year Success Rate
12/40 ratings generated profit
1 Year Average Return
-9.20%
reiterated a buy rating 17 days ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -9.20% per trade.
---